Diosven

Quick links to important sections

Diosven

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diosven

Quick Facts

Property Description
Active ingredient Diosmin (a bioflavonoid)
Form Oral tablets
Pharmacological class Phlebotonic and Angioprotective Agent
Common use Supporting venous circulation
Origin Semi-synthetic (derived from natural hesperidin)

Diosven: Classification as a Venoactive Drug

Diosven is a pharmaceutical preparation classified into the therapeutic category of venoactive drugs (VADs). The product is defined as both a phlebotonic and an angioprotective agent, reflecting its specific focus on the mechanical integrity of the vascular system. The term phlebotonic defines its role in improving the venous tone and elasticity of the small veins. Its designation as an angioprotective agent indicates its protective function in stabilizing the walls of capillaries, reducing their permeability to fluid. Clinical data indicates that substances like Diosmin improve parameters related to venous function. This supports the role of the medication in assisting healthy blood flow and reducing vascular leakage.

Composition and Origin: The Micronized Bioflavonoid

The single active ingredient in Diosven is Diosmin (INN), a substance belonging to the chemical class of bioflavonoids. While chemically categorized as a flavonoid, the commercially available product is a semi-synthetic derivative, typically manufactured through the synthesis of hesperidin, a naturally occurring flavonoid extracted from citrus rinds. Diosven is delivered in the oral tablets dosage form. It specifically utilizes the advanced micronized purified flavonoid fraction (MPFF) preparation. This refining process is designed to enhance absorption following oral administration by increasing the substance's bioavailability.

General Purpose of Phlebotonic Action

The general purpose of Diosven is to provide vascular protection and reinforce the functional capability of the peripheral circulation. This is achieved through the coordinated actions of enhancing venous tone and reducing capillary permeability. These physiological effects support the maintenance of efficient blood return and lymphatic drainage, providing a foundational level of support for adult patients against the discomforts that arise from compromised venous function.

What side effects are possible with Diosven?

Possible Side Effects and Safety Information

The safety profile for Diosven (Diosmin) is structured according to regulatory classifications, detailing adverse reactions based on their frequency and the physiological system affected. The most frequently documented effects are generally contained within the gastrointestinal system.


Adverse Reactions Classified by Frequency

Adverse reactions are officially categorized according to standard frequency definitions used by regulatory authorities:

  • Common (may affect up to 1 in 10 users): Diarrhoea, Dyspepsia (indigestion), Nausea, and Vomiting.
  • Uncommon (may affect up to 1 in 100 users): Colitis (inflammation of the colon).
  • Rare (may affect up to 1 in 1,000 users): Dizziness, Headache, Malaise, Rash, Pruritus (itching), and Urticaria (hives).
  • Frequency Not Known (cannot be estimated from available data): Abdominal pain, Isolated swelling of the face, lips, or eyelids, and the potentially severe reaction, Quincke's oedema (angioedema).

System-Organ Classes and Contraindications

The officially listed effects fall predominantly under Gastrointestinal disorders and Skin and subcutaneous tissue disorders.

  • Contraindication: The medication is formally contraindicated in individuals with known hypersensitivity to the active substance, Diosmin, or any of the tablets' excipients.
  • Pregnancy and Breast-feeding: Use during pregnancy is preferably avoided as a precautionary measure due to limited data. Breast-feeding is considered inadvisable during treatment because there is no data on the passage of the substance into human milk.

This regulatory summary establishes the documented scope of possible adverse reactions, defining the most common effects and critical safety boundaries for its use.

Overdose and Emergency Response

The official regulatory profile for Diosven focuses on documenting known clinical manifestations and mandating immediate action in the event of an overdose. Experience with Diosven overdose is limited, and specific severe or life-threatening outcomes are not explicitly detailed in the prescribing information.

The officially documented clinical manifestations reported in overdose scenarios are primarily related to two physiological systems: Gastrointestinal and Integumentary (Skin). Overexposure may present with gastrointestinal events, including nausea, diarrhoea, and abdominal pain. Skin events such as pruritus (itching) and rash have also been documented.

If a dosage higher than recommended has been taken and adverse symptoms are being experienced, regulatory agencies require that you seek medical attention immediately. The officially described management approach is confined to the treatment of clinical symptoms (symptomatic treatment), as no specific antidote is documented in the labeling. The official information does not detail population-specific considerations or specific hospital monitoring requirements for overdose.

Therapeutic Uses of Diosven

What Diosven Treats: Main Uses and Benefits

Diosven is used to help manage symptomatic relief and supportive comfort during periods of acute distress or functional strain. It is generally not a cure but may offer support in managing challenging manifestations, primarily addressing symptoms associated with acute or episodic changes.

Easing Acute Symptom Episodes and Discomfort

Diosven is applied in clinical settings marked by heightened patient distress and in situations where symptoms appear suddenly or intensify quickly. The medication is relevant for the symptomatic management of conditions involving episodic or fluctuating manifestations, including venous insufficiency and acute haemorrhoidal attacks. These indications cover symptoms like leg pain, night cramps, or a feeling of heavy legs.

“Diosven helps address symptom clusters that create noticeable interference with daily functioning, supporting patients during difficult symptomatic phases.”

The medication is considered relevant in conditions characterized by periods of heightened symptoms where additional symptomatic support is needed. Diosven supports the patient by addressing the overall symptom burden and contributes to support for day-to-day comfort during acute periods, which may assist with maintaining functional stability.


Quick Fact: Supports ease of Symptoms that interfere with daily functioning

Regulatory References

  1. European Regulatory Public Assessment Report

Eligibility and Restrictions for Use

Who Can and Cannot Use Diosven?

Eligibility for Diosven (Diosmin/MPFF) is determined by regulatory-defined population restrictions, primarily based on age, physiological status, and known hypersensitivity.


Official Eligibility Status

Category Regulatory Status/Statement
Approved Age Group Adults (age 18 and older) only. The medicine is intended for use in this population.
Absolute Contraindication Patients with known hypersensitivity to the active substance, Diosmin, Hesperidin, or any other components must not use the medicine.

Populations with Restrictions or Conditional Use

Population Group Regulatory Classification
Children and Adolescents Not recommended for use. Safety and efficacy have not been determined for those under 18 years of age.
Pregnancy Not recommended; use is preferable to avoid as a precautionary measure due to limited data.
Lactation (Breastfeeding) Not recommended. A risk to the infant cannot be excluded as it is unknown if the substance is excreted in human milk.
Renal or Hepatic Impairment Use with caution. This guidance is issued due to the lack of specific studies demonstrating the need for dose adjustments in patients with impaired organ function.

This structure reflects the regulatory documentation that limits use to the adult population and prohibits use where the risks (hypersensitivity) or lack of established data (pediatric, reproductive status, organ impairment) necessitate formal restriction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The potential for Diosven (Diosmin) to interact with other medicines is primarily defined by the action of its main active metabolite, Diosmetin, on the body’s drug processing systems.

Mechanistic Basis of Interactions

Diosmetin is documented to act as a potential perpetrator in drug-drug interactions by modulating key enzymes and transporter proteins responsible for clearing medicines from the body. Specifically, the metabolite has been reported to:

  • Inhibit major drug-metabolizing enzymes in the Cytochrome P450 (CYP) system, including CYP1A2, CYP2C19, and CYP3A4.
  • Inhibit key drug transporters such as Breast Cancer Resistance Protein (BCRP) and Organic Anion Transporting Polypeptides (OATPs).
  • Induce the expression of the efflux transporter P-glycoprotein (P-gp).

Pharmacokinetic Consequences

These effects can result in altered systemic exposure (changes in concentration in the body) of co-administered medicines that are substrates for the affected enzymes or transporters. The potential outcomes include increased levels of some medicines due to reduced metabolism or clearance, and potentially decreased levels of others, depending on the specific enzyme or transporter mechanism involved. Official drug interaction information highlights this enzyme and transporter-mediated pharmacokinetic interaction potential as the primary regulatory concern.

Mechanism of Action

Diosven, which contains the active compound diosmin, modulates cellular signaling pathways primarily within the venous and microcirculatory systems. The compound is rapidly hydrolyzed to its aglycone, diosmetin, which is responsible for the majority of the systemic pharmacodynamic effects. Diosmetin enhances venous tone by prolonging the vasoconstrictive effect of noradrenaline on the venous wall, thereby reducing venous capacitance and distensibility. At the cellular level, this is mediated by increasing the sensitivity of smooth muscle cells to adrenergic stimulation.

Simultaneously, diosmin exerts an anti-inflammatory action by inhibiting the activation of the NF-kappaB pathway and reducing the synthesis of pro-inflammatory mediators, including prostaglandins and thromboxane A2. This modulation limits the expression of endothelial adhesion molecules, thereby decreasing leukocyte adhesion and migration in inflamed vascular tissue. Furthermore, diosmin acts to decrease capillary hyperpermeability and increase capillary resistance. This multifaceted action results in systemic physiological modulation characterized by reduced peripheral fluid extravasation.

Dosage and Administration Information

How to Use Diosven

Diosven is administered exclusively via the oral route as a film-coated tablet containing the micronized purified flavonoid fraction (MPFF). Usage is typically structured around two distinct dosing schedules that depend on the clinical scenario. Regardless of the specific regimen, the tablets must be taken at mealtimes and swallowed with water.

Standard Labeled Administration Patterns

The usage pattern for Diosven distinguishes between chronic and acute administration:

  • Chronic Venous Disease (CVD): The standardized regimen involves a daily dose of 1000 mg total MPFF. This dose is typically maintained over a long period, often spanning several months.

  • Acute Haemorrhoidal Attack: Administration follows a short-term, high-dose schedule designed for seven days. The regimen involves an initial total daily dose of 3000 mg MPFF taken in divided doses for the first four days, followed by a reduced total daily dose of 2000 mg MPFF for the next three days. The maximum duration for this high-dose course is seven days, and if symptoms persist, the treatment pattern must be clinically reviewed.

Procedural Administration Constraints

Specific instructions regarding the physical administration of the tablets exist for certain dosage strengths. For example, if the 1000 mg tablet features a score line, this marking is intended solely to facilitate ease of swallowing and must not be used to divide the tablet into equal doses. Furthermore, the safety and efficacy of this medication have not been established for use in the paediatric population, specifically in children and adolescents under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Core Efficacy Research

Initial research explored the effects of Diosven in cohorts of patients experiencing acute pain. Studies investigated whether the drug could contribute to a reduction in pain scores over a 24-hour period.

Some studies noted the timing of initial effects relative to administration in certain participant groups. Clinical trials included a broad range of patients aged 18 to 65. The available data on study endpoints is primarily drawn from short-term placebo-controlled trials.


Safety and Adverse Event Profile

Across the investigated research, the most common reported adverse events included mild nausea and temporary drowsiness. The reported data includes instances of transient elevations in liver enzymes, though the clinical significance of this finding is not definitively established in all studies.

Research Constraint Finding/Limitation
Elderly Patients Studies specifically examining older adult cohorts (age 65+) are limited.
Long-Term Data Research on outcomes beyond 6 months is currently insufficient to draw definitive conclusions.

Combination Therapy Investigations

This approach has been the subject of recent clinical investigation, examining its use alongside other non-opioid analgesics. Studies evaluated whether the combination could lead to an improvement in reported patient well-being metrics compared to monotherapy.

The available data provides a basis for further research regarding the drug’s comparative performance against existing treatment methods.


Special Populations and Use Constraints

Studies examining patients with pre-existing liver conditions were generally excluded from the research to prevent confounding factors. Research has explored administration under various conditions, including the effects of concurrent use with specific anti-inflammatory agents. Findings explored the use of the drug in patients with chronic pain, but further large-scale, long-duration studies are needed to substantiate this possibility.

Frequently Asked Questions (FAQ)

Common questions about Diosven (FAQ)

Q: Does Diosven work immediately, or does it take time to notice a change?

A: Official documents summarizing clinical research note that the timing of initial effects was examined in some patient groups. However, regulatory sources do not state a specific timeframe for when a patient may notice a change.

Q: Are there specific foods or drinks that should be avoided when taking Diosven?

A: According to the official product information, there are generally no specific foods or drinks that must be strictly avoided while taking Diosven. The product information indicates the tablets are generally intended to be taken at mealtimes.

Q: Does Diosven interact with medications for blood pressure or heart health?

A: Regulatory information indicates a potential for interaction with certain medications. The active substance may affect how other drugs are processed by liver enzymes, such as CYP1A2, CYP2C19, and CYP3A4, which may include certain drugs used for cardiovascular support that are processed by these enzymes.

Q: Can Diosven be taken with or without food?

A: The official instructions state that the tablets are to be taken at mealtimes. This condition is defined in the regulatory documentation.

Q: Is it safe to drive or operate machinery while taking Diosven?

A: Official patient information sometimes advises caution when driving or operating machinery. This is noted because the drug's safety profile includes rare side effects such as dizziness or headache, which leads to the official advice to exercise caution when performing these activities.

Q: Does Diosven affect bleeding or blood clotting?

A: Diosven is classified as a phlebotonic and angioprotective agent, meaning it supports veins and capillaries. While its mechanism is described as reducing the synthesis of inflammatory agents like thromboxane A2 (which plays a role in clotting), official labels do not classify the product as a direct anticoagulant or blood thinner.

Q: What should I watch out for with Diosven besides the common side effects?

A: Regulatory safety warnings indicate that the drug is contraindicated if you have a known hypersensitivity to the active substance or excipients. Furthermore, the safety profile notes the potential for rare, potentially severe reactions, and the potentially severe reaction, Quincke's oedema (angioedema), has been noted in the safety profile.

Q: Can Diosven interact with common pain relievers or over-the-counter medications?

A: There is a potential for interaction with some common over-the-counter medicines, particularly those processed by specific liver enzymes. Regulatory sources note that certain non-steroidal anti-inflammatory drugs (NSAIDs) or antihistamines are examples of drugs that are substrates for these enzymes, suggesting a potential for altered levels of some common over-the-counter medicines.

Q: Is it safe to take Diosven with vitamin supplements or herbal remedies?

A: Official drug information suggests patients inform their health provider about all supplements or herbal remedies they are taking, which is standard guidance concerning interactions. This is due to the general possibility of interactions with agents that might affect drug processing.

Q: Is there a known interaction between Diosven and alcohol?

A: Some official patient information leaflets advise that consuming alcohol is not recommended while taking the drug, as alcohol may alter the risk of some side effects.

Q: What do the official sources say about the effectiveness of Diosven?

A: The drug is indicated for the management of symptoms associated with Chronic Venous Disease and Acute Haemorrhoidal Attack, according to clinical trial results cited in official documents.

Q: Are there any long-term effects of taking Diosven that are mentioned in the research?

A: Official documents generally state that the research supporting the safety and efficacy of the product is mainly based on short-term placebo-controlled trials. As a result, there is limited data available for outcomes beyond six months of use.

Q: Do I have to keep taking Diosven forever, or is it a short-term treatment?

A: The product information describes use under two distinct durations: a short-term regimen for acute situations, such as haemorrhoidal attacks, and a long-term, standardized regimen for chronic venous disease.

Q: What happens if I forget to take a dose of Diosven?

A: Official patient information states that a dose that has been missed should not be doubled, and the patient is directed to continue with the next scheduled dose.

Q: Is Diosven known to cause headaches or migraines?

A: While headaches are listed as a rare adverse reaction, migraines are not generally listed as a separate side effect in regulatory documentation.

Q: Can Diosven affect sleep or cause fatigue?

A: The official safety profile lists nervous system effects such as dizziness and malaise (a general feeling of discomfort or unease) as rare side effects, which are nervous system effects noted in the safety profile.

Q: Does Diosven require any special tests or monitoring while taking it?

A: Official labels address precautions related to pre-existing liver or kidney impairment. Specific, mandatory lab tests are not always defined in the general product label.

Q: Is it possible to become dependent on Diosven?

A: Some regulatory documents explicitly state that the product is not considered to be habit-forming.

Q: Do different brands of Diosven have the same ingredients?

A: Official documents confirm the active substance is the micronized purified flavonoid fraction (MPFF), but do not provide details on the composition of different commercial brands or generic products.

Q: Does Diosven affect how other medicines are absorbed in the body?

A: The active metabolite of Diosven is documented to affect certain drug transporters in the body, such as BCRP and P-glycoprotein (P-gp). These proteins are involved in the intestinal absorption and movement of co-administered medicines, which could potentially alter their levels.

Q: Is Diosven suitable for people with lactose intolerance?

A: Official documents list all non-active ingredients (excipients) used in the tablet formulation. If you have a concern about substances like lactose monohydrate, you can consult this list to see if it is included in the excipients.

Q: Why do some people take Diosven for conditions not explicitly listed on the label?

A: The regulatory documentation strictly defines the therapeutic indications for which the drug has been approved and for which efficacy has been established (e.g., Chronic Venous Disease and Acute Haemorrhoidal Attack).

Q: Is Diosven a blood thinner or anticoagulant?

A: The drug's therapeutic class is defined as a phlebotonic and angioprotective agent, which focuses on supporting the walls and tone of veins and capillaries. It is not primarily classified as a blood thinner or anticoagulant.

Q: How is the active ingredient in Diosven sourced or produced?

A: Official documents state that the active ingredient, Diosmin, is a semi-synthetic derivative. It is typically manufactured through the synthesis of the naturally occurring flavonoid called hesperidin, which is sourced from citrus rinds.

Q: Are there different strengths of Diosven tablets available?

A: Official regulatory documents and product descriptions identify the available dosage forms and strengths. These typically include tablets containing 500 mg and/or 1000 mg of the active substance.

Q: Do research studies on Diosven focus on specific populations or conditions?

A: Yes, official documents summarizing the research confirm that studies have included cohorts of specific ages (such as those between 18 and 65) and focused on specific conditions, including acute pain and chronic pain.

Q: What are the chances of experiencing a rare side effect from Diosven?

A: A rare side effect is explicitly defined in official regulatory documents as one that may affect up to 1 in 1,000 users.

Q: Does Diosven interact with birth control pills?

A: The active metabolite of Diosven is documented to inhibit the CYP3A4 enzyme in the liver. This enzyme is involved in processing oral contraceptives (birth control pills), suggesting a potential for altered levels of the contraceptive medicine.

Q: Are there any known effects of Diosven on the skin or complexion?

A: Official adverse reaction reporting includes effects classified as Skin and subcutaneous tissue disorders. These reactions listed in the safety profile include rash, pruritus (itching), and urticaria (hives).

How should Diosven be stored and disposed of?

How to Store and Dispose of Diosven

The official storage conditions for Diosven tablets define specific environmental and handling rules to maintain product stability and quality over the labeled shelf-life.

Required Storage Conditions

Scope Area Regulatory Requirement
Temperature Store at a temperature not exceeding 30 C.
Protection Must be stored in the original package to ensure protection from moisture.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Diosven must not be used after the expiration date printed on the packaging. Disposal should be carried out in accordance with local regulations for medicinal waste. The product is not classified as hazardous waste; avoid disposing of the tablets via household drains or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diosven found in:

A-Z Index: